Efficacy and Safety of DTG/3TC among Treatment-Naïve Individuals
ViiV Healthcare welcomes investigator-sponsored research that advances understanding of DTG/3TC in the treatment of HIV among treatment-naïve individuals. Research of interest may include real-world effectiveness, barrier to resistance, safety and tolerability, patient and provider experience, and health-related quality of life. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.
ViiV ISR Area Of Interest Overview Drug/Product Alignment ViiV Products in Scope: Dolutegravir
Treatment Type: Treatment
Specify the Treatment Type:
Area of Interest/DataGap Description Core Focus Area: Efficacy/Effectiveness, Experience and Preference
Example Research Question(s): • What is the efficacy and safety of DTG/3TC in acute HIV infection? • What are the treatment outcomes of DTG/3TC vs BIC/FTC/TAF in treatment-naïve individuals with rapid ART initiation? • What is the efficacy and barrier to resistance of DTG/3TC vs BIC/FTC/TAF in treatment-naïve individuals at risk of non-adherence? • What is the impact of DTG/3TC on overall health and wellbeing for treatment naive individuals, as determined by patient reported outcomes and/or patient experience? • What are the drivers for DTG/3TC decision/choice among treatment naïve individuals and physicians?
Desirable Study Parameters Populations of Interest: Treatment Naïve
Geographical Regions: Global
Version 20250909-disp